New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTRGEN, RGEN, NXTM, NXTM, ABMD, ABMDStephens to hold a bus trip
Medical Technology Boston Bus Trip travels throughout Boston on August 12.
News For RGEN;NXTM;ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
08:02 EDTNXTMNxStage Medical presents four positive abstracts for NxStage System One
NxStage Medical announced the presentation of four new abstracts demonstrating clinical outcomes during the National Kidney Foundation's Spring Clinical Meeting in Dallas, Texas. Three of the abstracts highlight improved survival, reduced cardiovascular hospital readmissions, and increased transplantation for daily home hemodialysis patients using the NxStage® System One versus other modalities. The fourth abstract details results from the company's study that led to the clearance of the System One as the first and only hemodialysis machine cleared for home nocturnal hemodialysis. The first three abstracts show: 29% lower risk of death for incident patients using DHHD vs. patients receiving conventional in-center hemodialysis, 15% lower risk of 30-day readmission after hospitalization for heart failure than peritoneal dialysis (PD) patients and 27% lower than IHD patients, and 37% greater incidence of transplant for DHHD patients than PD patients, and 22% greater than IHD patients.
March 24, 2015
16:20 EDTABMDOn The Fly: Closing Wrap
Subscribe for More Information
12:44 EDTABMDOn The Fly: Midday Wrap
Subscribe for More Information
11:04 EDTABMDAbiomed retraces gains, levels to watch
Subscribe for More Information
09:22 EDTABMDOn The Fly: Pre-market Movers
Subscribe for More Information
March 23, 2015
19:13 EDTABMDOn The Fly: After Hours Movers
Subscribe for More Information
17:47 EDTABMDAbiomed confirms FDA approval of Impella 2.5 heart pump
Subscribe for More Information
17:17 EDTABMDFDA approves Impella 2.5 System
The U.S. FDA approved the Impella 2.5 System, a miniature blood pump system intended to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention procedures, such as balloon angioplasty and stenting, which re-open coronary arteries that are narrowed or blocked due to severe coronary artery disease. The Impella 2.5 System is manufactured by Abiomed, based in Danvers, Massachusetts. Reference Link
11:15 EDTRGENRepligen management to meet with Stephens
Meetings to be held in Minneapolis on March 25 and in Chicago on March 26 hosted by Stephens.
March 19, 2015
07:17 EDTABMDStephens to hold a conference
Subscribe for More Information
March 13, 2015
07:04 EDTRGENRepligen sees FY15 revenue $72M-$75M, consensus $70.5M
Sees FY15 product gross margin 55%-57%. Total income from operations for FY15 is expected to be $12M-$14M, and net income is expected to be $8M-$10M, reflecting estimated taxes of approximately $4M.
07:02 EDTRGENRepligen reports Q4 EPS (1c), consensus 4c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use